Treatment-resistant anxiety disorders
The DOI matches its Crossref record; 86 of the 88 references it cites were found in a registry or an index.
Abstract
Several epidemiological studies confirmed that Anxiety Disorders as a group are the most prevalent psychiatric conditions in the United States. The importance of these conditions is underlined by the fact that they cause significant disability, poor quality of life, alcohol and drug abuse. Anxiety disorders are treatable conditions and respond to the front-line interventions such as serotonin reuptake inhibitors and cognitive behavioral therapy. However, only about 60% of patients respond to those treatments to any significant degree. Many still have residual symptoms or stay treatment refractory. The group of anxiety patients that is resistant to the treatment has been shown to have very poor quality of life and have highest rate of suicidal attempts than any other disorders. Many biological, treatment specific and social factors are affecting treatment resistance. In this paper, we are attempting to review reasons for the treatment resistance. In addition, we would like to review current strategies that could be helpful in reducing treatment resistance and aiding people chronically suffering from these severe and disabling conditions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, comorbid anxiety and depression is associated with more severe somatic symptoms, poorer social functioning, greater suicidal ideation and a higher likelihood of prescription of benzodiazepines, as well as poorer treatment response.13,14”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“For example, comorbid anxiety and depression is associated with more severe somatic symptoms, poorer social functioning, greater suicidal ideation and a higher likelihood of prescription of benzodiazepines, as well as poorer treatment response.13,14”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Several factors are associated with treatment-resistant anxiety, including comorbid physical and mental health conditions, noncompliance and environmental stressors.13”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Physical and mental health comorbidity (e.g.depression, other anxiety disorders, personality disorders, mild cognitive deficits, physical ill-health, pain) is common in TR-GAD and is associated with poor treatment response.13”
From Acceptance and commitment therapy for older people with treatment-resistant generalised anxiety disorder: The FACTOID feasibility study (2021) · cites this paper as [13]
In the citing paper
“Although treatment for anxiety disorders produces moderate QOL improvements, not all individuals respond to these front-line interventions, and those who are treatment refractory exhibit particularly low QOL and increased rates of suicide [85].”
From Correlates of Quality of Life in Anxiety Disorders: Review of Recent Research (2021) · cites this paper as [85]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Prevalence and Treatment of Mental Disorders, 1990 to 2003
Kessler, R. C., Demler, O., Frank, R. G., Olfson, M., Pincus, H. A., Walters, E. E., Wang, P., Wells, K. B., & Zaslavsky, A. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmsa043266 · Cited by 1,910
The Emotional Brain, Fear, and the Amygdala
LeDoux, J. (2003) · Cellular and Molecular Neurobiology · doi:10.1023/a:1025048802629 · Cited by 1,818
Neuroanatomical Hypothesis of Panic Disorder, Revised
Gorman, J. M., Kent, J. M., Sullivan, G. M., & Coplan, J. D. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.493 · Cited by 1,004
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Neuroimaging and frontal–subcortical circuitry in obsessive–compulsive disorder
Saxena, S., Brody, A. L., Schwartz, J. M., & Baxter, L. R. (1998) · British Journal of Psychiatry · doi:10.1192/s0007125000297870 · Cited by 831
Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy
Morris, G. L., Mueller, W. M., & The Vagus Nerve Stimulation Study Group E–E (1999) · Neurology · doi:10.1212/wnl.53.8.1731 · Cited by 724
Groves, D. A., & Brown, V. J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.01.004 · Cited by 675
Research works printed but not linked: 5
- Nemeroff CB . Remission: today's target in the treatment of mood and anxiety disorders. Psychopharmacol Bull 2002; 36: 5.
- Pollack MH, Meoni P, Otto MW, Simon N, Hackett D . Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long term studies. J Clin Psychopharmacol 2003; 23: 250–259.
- Barlow DH, Gorman JM, Shear MK, Woods SW . Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA 2000; 283: 2529–2536. · DOI · Paper page
- Beale MD, Kellner CH, Pritchett JT, Burns CM . ECT for OCD. J Clin Psychiatry 1995; 56: 81–82.
- Rush AJ, Marangell LB, Sackeim HA, George MS, Brannan SK, Davis SM et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005; 58: 347–354. · DOI · Paper page
Cited by
Items 101–200 of 289
An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol
Garakani, A., Freire, R. C. R., Buono, F. D., Thom, R. P., Larkin, K., Funaro, M. C., Salehi, M., & Pérez-Rodríguez, M. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0269772 · Cited by 31
“Despite the presence of treatment options, there has been limited research done on the management of patients with treatment-resistant or refractory anxiety [7].”
BackgroundXie, L., Hu, P., Guo, Z., Chen, M., Wang, X., Du, X., Li, Y., Chen, B., Zhang, J., Zhao, W., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03053-0 · Cited by 34
“About 30% of patients still cannot receive effective treatment [6 – 8].”
Anxiety disorders: Treatments, models, and circuitry mechanisms
Ren, L., Fan, Y., Wu, W., Qian, Y., He, M., Li, X., Wang, Y., Yang, Y., Wen, X., Zhang, R., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176994 · Cited by 45
Lee, A. R. Y. B., Yau, C. E., Mai, A. S., Amanda, T. W., Ong, B. S. Y., Yam, N. E., & Ho, C. S. H. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223221140390 · Cited by 30
Wray, T. B., Kemp, J. J., & Larsen, M. A. (2023) · Cognitive Behaviour Therapy · doi:10.1080/16506073.2023.2229017 · Cited by 25
“These disorders are also very responsive to available treatments (Barlow & Lehman, 1996; Bystritsky, 2006).”
BackgroundTaylor, J. J., Li, J., Lin, C., Jones, E., Frandsen, S. B., Becker, C. R., Drew, W., Haj-Darwish, D., Jabbour, S., Leach, J., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03535-1 · Cited by 30
Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C. R., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19203 · Cited by 31
VanderZwaag, J., Halvorson, T., Dolhan, K., Šimončičová, E., Ben‐Azu, B., & Tremblay, M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03772-0 · Cited by 30
A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects
Hartland, H., Mahdavi, K., Jelen, L. A., Strawbridge, R., Young, A. H., & Alexander, L. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231161627 · Cited by 32
“Benzodiazepines provide rapid relief of acute anxiety symptoms, but are associated with tolerance and dependence (Bystritsky, 2006; Cassano et al., 2002).”
BackgroundEilertsen, S. E. H., & Eilertsen, T. (2023) · BMC Psychology · doi:10.1186/s40359-023-01238-8 · Cited by 34
“However, a large proportion of patients do not recover from treatment, and many still have symptoms after treatment [8, 9].”
BackgroundA clinical staging approach to improving diagnostics in anxiety disorders: Is it the way to go?
Bokma, W. A., Batelaan, N. M., Hoogendoorn, A. W., Penninx, B. W. J. H., & van Balkom, A. J. L. M. (2019) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867419887804 · Cited by 31
“Australian & New Zealand Journal of Psychiatry, 54(2) has recovered from the disability (Bystritsky, 2006; Hovenkamp-Hermelink et al., 2016; Iancu et al., 2014; Lamers et al., 2011; Scholten et al., 2016).”
BackgroundMullally, M., Kramp, K. L., Cayer, C., Saleem, A., Ahmed, F., McRae, C., Baker, J. P., Goulah, A., Otorola, M., Sanchez, P., et al. (2010) · Phytotherapy Research · doi:10.1002/ptr.3246 · Cited by 23
“Treatments include cognitive behaviour therapy and pharmacological interventions, but only 60% of patients are responsive to treatment (Bystritsky, 2006) and the common pharmaceuticals used to treat anxiety, benzodiazepines (BDZs), are associated with serious side effects and not recommended for…”
BackgroundEngineering brain activity patterns by neuromodulator polytherapy for treatment of disorders
Ghannad‐Rezaie, M., Eimon, P. M., Wu, Y., & Yanik, M. F. (2019) · Nature Communications · doi:10.1038/s41467-019-10541-1 · Cited by 23
Yoga as an Integrative Therapy for Mental Health Concerns: An Overview of Current Research Evidence
Park, C. L., & Slattery, J. M. (2021) · Psychiatry International · doi:10.3390/psychiatryint2040030 · Cited by 38
“Approximately 30% of patients recover with standard pharmacology treatments, while another 30–40% are considered improved [15].”
BackgroundRole of Proteomics in Biomarker Discovery
Patel, S. (2014) · Advances in protein chemistry and structural biology · doi:10.1016/b978-0-12-800168-4.00003-2 · Cited by 28
Spinhoven, P., Hoogerwerf, E., van Giezen, A. E., & Greeven, A. (2022) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2022.102599 · Cited by 31
Does exercise augment operant and Pavlovian extinction: A meta-analysis
Roquet, R. F., & Monfils, M. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2017.09.018 · Cited by 25
Højlund, M., Kafalı, H. Y., Kırmızı, B., Fusar‐Poli, P., Correll, C. U., Cortese, S., Sabé, M., Fiedorowicz, J. G., Saraf, G., Zein, J., et al. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.09.011 · Cited by 25
Campbell‐Sills, L., Roy‐Byrne, P., Craske, M. G., Bystritsky, A., Sullivan, G., & Stein, M. B. (2016) · Depression and Anxiety · doi:10.1002/da.22574 · Cited by 26
Self-citationGordon, B. R., McDowell, C. P., Lyons, M., & Herring, M. P. (2020) · Mental health and physical activity · doi:10.1016/j.mhpa.2020.100321 · Cited by 21
Cox, J., Thakur, B., Alvarado, L., Shokar, N. K., Thompson, P. M., & Dwivedi, A. K. (2022) · Annals of Clinical Psychiatry · doi:10.12788/acp.0067 · Cited by 27
Shackman, A. J., Fox, A. S., & Seminowicz, D. A. (2015) · Behavioral and Brain Sciences · doi:10.1017/s0140525x14001010 · Cited by 23
Pharmacotherapy for Anxiety Disorders.
O’Leary, K. B., & Khan, J. S. (2024) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2024.04.012 · Cited by 22
Targeted drug release from stable and safe ultrasound-sensitive nanocarriers
Wilson, M. G., Parikh, A., Dara, A., Beaver, A. S., & Kubanek, J. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1408767 · Cited by 21
“Pharmacological treatments are often curbed by intolerable side effects or low effectiveness of drugs (Lyons and Pahwa, 2004; Bystritsky, 2006; Zesiewicz et al., 2010; Al-Harbi, 2012; Elias et al., 2013; Elias et al., 2016; Jaffe et al., 2019).”
Antipsychotic agents in anxiety disorders: An umbrella review
Garakani, A., Buono, F. D., Salehi, M., Funaro, M. C., Klimowicz, A., Sharma, H., Faria, C. G. F., Larkin, K., & Freire, R. C. R. (2024) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13669 · Cited by 20
“12,13 Although there is no consensus definition of treatment-resistant anxiety, one that has been proposed is when a patient fails to respond to one of two first-line treatments, either CBT or medications like an SSRI or SNRI.”
BackgroundRemus: System for remote deep brain interventions
Webb, T. D., Wilson, M. G., Odéen, H., & Kubanek, J. (2022) · iScience · doi:10.1016/j.isci.2022.105251 · Cited by 16
Genetic modulation of the HTR2A gene reduces anxiety-related behavior in mice
Rohn, T. T., Radin, D. I., Brandmeyer, T., Linder, B., Andriambeloson, E., Wagner, S., Kehler, J., Vasileva, A., Wang, H., Mee, J. L., et al. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad170 · Cited by 21
Dang, B. H., Halavi, S. E., Rotstein, N. M., Spivak, N. M., Dang, N. H., Cvijanovic, L., Hiller, S., Martelo, M. V., Rosenberg, B. M., Swenson, A., et al. (2024) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2024.100342 · Cited by 24
“Nearly 40% of patients do not respond to fi rst-line treatments [e.g., cognitive behavioral therapy and pharmacological interventions (12)], highlighting the necessity to advance alternative and augmentative treatments.”
Gomez-Escolar, A., Folch‐Sanchez, D., Stefaniuk, J., Swithenbank, Z., Nisa, A., Braddick, F., Chaudhary, N. I., van der Meer, P. B., & Batalla, A. (2024) · CNS Drugs · doi:10.1007/s40263-024-01101-3 · Cited by 22
“About a third of patients with anxiety disorders [10, 11], depression [10, 12] or psychotic spectrum disorders are regarded as treatment-resistant (not responding to two adequate doses and duration of medication) [10–12].”
Ballanger, B., Bath, K. G., & Mandairon, N. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.06.007 · Cited by 24
Zaig, I. F., Azem, F., Schreiber, S., Amit, A., Litvin, Y. G., & Bloch, M. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07805 · Cited by 19
O'Connor, S. M., Sleebs, B. E., Street, I. P., Flynn, B. L., Baell, J. B., Coles, C., Quazi, N., Paul, D., Poiraud, E., Huyard, B., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.109836 · Cited by 15
“These newer generation antidepressants offer an improved therapeutic option and around 25% of responders achieve recovery or remission (Bystritsky, 2006; Berger et al., 2009).”
Domschke, K., Schiele, M. A., Salvador, Ó. C., Zillich, L., Lipovsek, J., Pittig, A., Heinig, I., Ridderbusch, I. C., Straube, B., Richter, J., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03038-5 · Cited by 21
“This is partly due to treatment resistance to fi rst-line pharmacological or cognitive behavioral therapy (CBT) in 20 – 50% of patients [5 – 8] contributing to a substantial chronicity, with anxiety disorders ranking 6th among all disorders regarding the years lived with disability (YLDs) worldwide…”
Schiele, M. A., Reif, A., Lin, J., Alpers, G. W., Andersson, E., Andersson, G., Arolt, V., Bergström, J., Carlbring, P., Eley, T. C., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.01.004 · Cited by 18
“…treatment of anxiety disorders, effective pharma- cological and psychotherapeutic options are available, how- ever, over one third to 50% of patients with anxiety disorders do not respond to the initial mode of treatment in a clini- cally significant way ( Bystritsky, 2006 ; Loerinc et al., 2015 ).”
BackgroundNo effect of glucose administration in a novel contextual fear generalization protocol in rats
Luyten, L., Schroyens, N., Luyck, K., Fanselow, M. S., & Beckers, T. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.183 · Cited by 16
Casaril, A. M., Lourenço, D. D. A., Domingues, M., Smaniotto, T. Â., Birmann, P. T., Vieira, B. M., Sonego, M. S., Seixas, F. K., Collares, T. V., Lenardao, E. J., et al. (2021) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2021.100054 · Cited by 17
“[20] and more than 15% of anxious patients [21] do not respond to the currently available pharmacotherapy, stimulating the search for better therapeutic strategies.”
BackgroundVance, D. E., Dodson, J. E., Watkins, J., Kennedy, B. H., & Keltner, N. L. (2013) · Journal of Neuroscience Nursing · doi:10.1097/jnn.0b013e3182829038 · Cited by 19
“This treatment resistance may be because of multiple factors such as genetics, social factors, and comorbidities such as substance abuse (Bystritsky, 2006).”
BackgroundEffects of ascorbic acid on anxiety state and affect in a non-clinical sample
Moritz, B., Schwarzbold, M. L., Guarnieri, R., Díaz, A. P., Rodrigues, A. L. S., & Dafré, A. L. (2017) · Acta Neurobiologiae Experimentalis · doi:10.21307/ane-2017-068 · Cited by 17
Tsirmpas, C., Andrikopoulos, D., Fatouros, P., Eleftheriou, G., Anguera, J. A., Kontoangelos, K. A., & Papageorgiou, C. (2022) · Frontiers in Digital Health · doi:10.3389/fdgth.2022.868970 · Cited by 17
“At the same time, subjective and patient-related factors (27) such as the severity of symptoms, comorbidities, and cultural beliefs, as well as limited response to medication due to underlying pathological conditions (27, 34) might hinder the overall efficacy of a treatment protocol, leaving an estimated 30%-40% of pa…”
BackgroundByeon, J., Moon, J., Je, S. R., Park, S. H., & Kim, J. W. (2023) · Scientific Reports · doi:10.1038/s41598-023-30994-1 · Cited by 17
Fulton, H. G., Barrett, S. P., MacIsaac, C., & Stewart, S. H. (2011) · Harm Reduction Journal · doi:10.1186/1477-7517-8-18 · Cited by 16
Truppman Lattie, D., Nehoff, H., Neehoff, S., Gray, A., & Glue, P. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120953991 · Cited by 13
“Co-morbidity is extremely common in patients with refractory anxiety disorders (Bystritsky, 2006; Stein et al., 2017), and we believe our cohort represents a real-world population In addition, our cohort had significant anxiety severity, ranking in the 90th percentile for FQ-SP and FQ-Ag and in the…”
BackgroundWebler, R. D., Oathes, D. J., van Rooij, S. J. H., Gewirtz, J. C., Nahas, Z. H., Lissek, S. M., & Widge, A. S. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.105005 · Cited by 15
Nicholson, J. R., & Sommer, B. (2018) · Brain and Neuroscience Advances · doi:10.1177/2398212818804030 · Cited by 15
“Application of such know-how could help understanding of why some patients respond to certain drugs and others not; it is indeed estimated that over one-third of patients suffering from anxiety-related disorders are treatment resistant (Bystritsky, 2006).”
BackgroundKobayashi, K., Mikahara, Y., Murata, Y., Morita, D., Matsuura, S., Segi‐Nishida, E., & Suzuki, H. (2020) · iScience · doi:10.1016/j.isci.2020.101025 · Cited by 13
Bases fisiológicas e medicamentosas do transtorno da ansiedade
Lima, C. L. S., Lira, S. M., Holanda, M. O., da Silva, J. Y. G., Moura, V. B., Oliveira, J. D. S. M., Serra, B. F., Freitas, A. G. Q., Girão, N. M., & Guedes, M. I. F. (2020) · Research Society and Development · doi:10.33448/rsd-v9i9.7780 · Cited by 24
Somatostatin: Linking Cognition and Alzheimer Disease to Therapeutic Targeting
Sandoval, K. E., & WITT, K. A. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001117 · Cited by 20
“Moreover, the SST 4 agonist peripheral actions that have been identified are inflammatory-state dependent, with the capacity to mitigate inflammatory associated pain (Helyes et al., 2001, 2006, 2009, Lei et al., 2014; Elekes et al., 2008; Van Op den Bosch et al., 2009).”
InfluentialKambhampati, S., Banerjee, S., Dhar, K., Mehta, S., Haque, I., Dhar, G., Majumder, M., Ray, G., VanVeldhuizen, P. J., & Banerjee, S. K. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0845 · Cited by 11
Predictors of Pharmacotherapy Response in Generalized Anxiety Disorder: A Systematic Review
Ferreira-Garcia, R., Mochcovitch, M. D., do Cabo, M. C., Nardi, A. E., & Freire, R. C. R. (2017) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000127 · Cited by 15
Bulteau, S., Laurin, A., Bach‐Ngohou, K., Péré, M., Vibet, M., Hardouin, J.-B., Sebille, V., Lagalice, L., Faurel-Paul, E., Acier, D., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11020345 · Cited by 13
“Pharmacological and cognitive behavioral therapies have proved their efficacy [4,5], but only half of patients respond [6,7], and one-third may discontinue their medication [8].”
BackgroundTranscranial Electrical Stimulation for Psychiatric Disorders in Adults: A Primer
Cho, H., Razza, L. B., Borrione, L., Bikson, M., Charvet, L. E., Dennis‐Tiwary, T. A., Brunoni, A. R., & Sudbrack-Oliveira, P. (2022) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20210020 · Cited by 18
“Unfortunately, of those treated, only few patients respond to fi rst-line pharmacological treatments (2).”
Myruski, S., Cho, H., Bikson, M., & Dennis‐Tiwary, T. A. (2021) · Frontiers in Neuroergonomics · doi:10.3389/fnrgo.2021.652162 · Cited by 12
“options (Bystritsky, 2006).”
BackgroundShackman, A. J., Fox, A. S., & Seminowicz, D. A. (2015) · Behavioral and Brain Sciences · doi:10.1017/s0140525x15000679 · Cited by 11
Gay, F., Singier, A., Aouizerate, B., Salvo, F., & Bienvenu, T. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.910897 · Cited by 14
Identification of drug repurposing candidates for the treatment of anxiety: A genetic approach
Woodward, D. J., Thorp, J. G., Akóṣílè, W., Ong, J., Gamazon, E. R., Derks, E. M., & Gerring, Z. F. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115343 · Cited by 12
Developing the language of futility in psychiatry with care
Wp, P. (2016) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v22i1.978 · Cited by 11
Prädiktive Faktoren bei Angststörungen
Domschke, K. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4047-1 · Cited by 10
Importância das técnicas de relaxamento na terapia cognitiva para ansiedade
Willhelm, A. R., Andretta, I., & Ungaretti, M. S. (2015) · Contextos Clínicos · doi:10.4013/ctc.2015.81.08 · Cited by 50
dos Anjos, L. C., Gomes, F. M. M., do Couto, L. L., Mourão, C. A., Moreira, K. G., Silva, L. P., & Mortari, M. R. (2016) · Life Sciences · doi:10.1016/j.lfs.2016.02.063 · Cited by 10
Fitzpatrick, C. M., Larsen, M., Madsen, L. H., Caballero-Puntiverio, M., Pickering, D. S., Clausen, R. P., & Andreasen, J. T. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000243 · Cited by 10
“Still, both disorders are conventionally treated with drugs that utilize monoaminebased mechanisms (Vaswani et al., 2003; Bystritsky, 2006).”
BackgroundStem cell-derived brain organoids for controlled studies of transcranial neuromodulation
Kubanek, J., Wilson, M., Rabbitt, R. D., Armstrong, C. J., Farley, A. J., Ullah, H. M. A., & Shcheglovitov, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18482 · Cited by 9
“One in three patients with a neurological or mental disorder does not respond to drugs or other forms of treatment [6,1,25,39,64, 14,15,17,26,38].”
BackgroundLi, A. Y., Erridge, S., Holvey, C., Coomber, R., Barros, D. A. R., Bhoskar, U., Crews, M., Donnelly, L., Imran, M., Korb, L., et al. (2024) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000536 · Cited by 12
“This is particularly important, considering the median daily THC dose was 100.00 mg/day, which is high relative to studies which have evaluated anxiety as an outcome in the past (Bystritsky, 2006; Ansara, 2020; Black et al ., 2019).”
InfluentialA theory of the anxiolytic action of flumazenil in anxiety disorders
Gallo, A. T., & Hulse, G. K. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221082466 · Cited by 10
“…non-responsiveness to the range of available pharmacotherapy treatments is observed in one in three anxiety diagnoses patients, and for whom the current pharmacological augmentation strategies are largely ineffective (Brown et al., 1996; Bystritsky, 2006; Patterson and Van Ameringen, 2016).”
BackgroundPharmacogenetics of anxiety disorders
McGowan, O. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134443 · Cited by 11
Talbot, A., Lee, C., Ryan, S., Roberts, N., Mahtani, K. R., & Albury, C. (2022) · BMC Family Practice · doi:10.1186/s12875-022-01819-3 · Cited by 18
“Many people live with these conditions [17, 18], and without this knowledge, we do not know what current care looks like, nor do we understand how services could be improved.”
BackgroundMedicinal cannabis in the management of anxiety disorders: A systematic review
Roberts, L., Sorial, E., Budgeon, C. A., Lee, K., Preen, D. B., & Cumming, C. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116552 · Cited by 12
“Despite this, there remains a clear unmet need surrounding treatment and ongoing management of anxiety-related disorders (Bystritsky, 2006).”
InfluentialXu, Y., Kappen, M., Peremans, K. Y., Bundel, D. D., Eeckhaut, A. V., Laeken, N. V., Vos, F. D., Dobbeleir, A. A., Saunders, J. H., & Baeken, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11061531 · Cited by 9
The therapeutic value of alstonine: An updated review
Olawale, F., Adetunji, T. L., Adetunji, A. E., Iwaloye, O., & Folorunso, I. M. (2022) · South African Journal of Botany · doi:10.1016/j.sajb.2022.11.047 · Cited by 8
Plasticity-augmented psychotherapy for refractory depressive and anxiety disorders
Choi, K., & Kim, Y. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.04.003 · Cited by 8
“In anxiety disorders, which share neurobiological aspects and treatment options with depression (Clark and Beck, 2010), patients with inadequate response to pharmacologic and non-pharmacological treatment represent up to 40% of the affected population (Bystritsky, 2006).”
Maunder, R., Wiesenfeld, L. A., Rawkins, S., & Park, J. (2016) · Journal of Comorbidity · doi:10.15256/joc.2016.6.66 · Cited by 7
Huang, C.-W., Chiu, Y., Chen, P., Yu, N., Tsai, H., & Chang, C. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12861 · Cited by 10
“First-line pharmacotherapy for anxiety disorder includes selective serotonin reuptake inhibitors and serotoninnorepinephrine reuptake inhibitors, tricyclic antidepressants, and benzodiazepines; however, the response to these medications is often limited, with frequent occurrence of treatment resistance.(9) Failure to…”
BackgroundDomschke, K., Kapfhammer, H., & Deckert, J. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_69 · Cited by 11
Cerne, R., Smith, J. L., Chrzanowska, A., & LIPPA, A. S. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173895 · Cited by 9
Roy, S., Colacicco, G., Frigeri, G., Tarantino, F., Matera, E., Petruzzelli, M. G., & Cortese, S. (2025) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2025.0029 · Cited by 8
Therapieresistenz bei Angsterkrankungen – Definition und Behandlungsoptionen
Domschke, K., Ströhle, A., & Zwanzger, P. (2024) · Der Nervenarzt · doi:10.1007/s00115-024-01627-3 · Cited by 11
“Ein Faktor, der zur Chronifizierung von Angsterkrankungen beiträgt, ist die relativ hohe Rate an Therapieresistenz, insbeson-dere bei der Panikstörung mit oder ohne Agoraphobie, der generalisierten Angst-störung und der sozialen Angststörung [10, 13, 16, 31, 39].”
Definition and Epidemiology of Treatment Resistance in Psychiatry
Smith-Apeldoorn, S. Y., Veraart, J. K. E., & Schoevers, R. A. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_1 · Cited by 11
Cho, H., Likhtik, E., & Dennis‐Tiwary, T. A. (2021) · Cognitive Affective & Behavioral Neuroscience · doi:10.3758/s13415-020-00855-9 · Cited by 11
“…do not respond to current “gold-standard” treatments, such as cognitive behavioral therapy (CBT; Beck, 1964) or selective serotonin reuptake inhibitors (Bystritsky, 2006), demonstrating significant gaps in our understanding of the mechanisms that underlie the etiology and remediation of anxiety.”
BackgroundMelanin-concentrating hormone receptor: A therapeutic target for novel anxiolytics
Chaki, S. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173818 · Cited by 6
Mulvaney, S. W., Dineen, K. J., Mahadevan, S., Desronvilles, R. J., & Olmsted, K. R. (2025) · Brain Sciences · doi:10.3390/brainsci15020188 · Cited by 6
“The published literature notes between 60 and 85% of patients respond to anxiety-specific medications and only 50% experience symptom relief [10].”
Mendis, K., Gnanapragasam, M. A., Keerthirathne, D. H. G. A. N., Madushani, L. A. N., Piyasekara, G. M. T. M., Senanayake, S., Bandara, C., Abeytunga, T. U., Gunaratna, T. A. N. R., & Jayakody, T. (2025) · Phytomedicine Plus · doi:10.1016/j.phyplu.2025.100794 · Cited by 6
Shadli, S. M., Delany, R. G., Glue, P., & McNaughton, N. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.900105 · Cited by 5
“Only some patients respond to the first drug they try, and some do not show any improvement even after trials with multiple drugs (Bystritsky, 2006; Aan Het Rot et al., 2012).”
BackgroundNeurobiological Mechanisms Underlying Psychological Dysfunction After Brain Injuries
Unadkat, P., Rebeiz, T. J., Ajmal, E., Souza, V. D., Xia, A., Jinu, J., Powell, K., & Li, C. (2025) · Cells · doi:10.3390/cells14020074 · Cited by 9
Jakovljević, M. (2015) · PubMed · Cited by 7
Understanding Anxiety in Borderline Personality Disorder
Bulbena‐Cabré, A., Pérez-Rodríguez, M. M., Porges, S. W., Bulbena, A., & Goodman, M. S. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0122-0 · Cited by 6
Anxiolytic Effect of Carvedilol in Chronic Unpredictable Stress Model
de Sousa, C. N. S., Medeiros, I. D. S., Vasconcelos, G. S., de Aquino, G. Â., Filho, F. M. S. C., de Almeida, J. C., Alves, A. P. N. N., Macêdo, D. S., Leal, L. K. A. M., & Vasconcelos, S. M. M. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/6906722 · Cited by 8
“Moreover, many still have residual symptoms or remain refractory to treatment; therefore, the search for new therapeutic strategies is urgent [18].”
Generalized anxiety disorder: advances in neuroimaging studies
Costa, M. D. A., & Manfro, G. G. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2019-4106 · Cited by 9
Gould, R. L., Wetherell, J. L., Serfaty, M. A., Kimona, K., Lawrence, V., Jones, R., Livingston, G., Wilkinson, P., Walters, K., Novere, M. L., et al. (2021) · Health Technology Assessment · doi:10.3310/hta25540 · Cited by 4
Schiele, M. A., Fagan, H. A., Baldwin, D. S., & Domschke, K. (2025) · Psychotherapy and Psychosomatics · doi:10.1159/000547926 · Cited by 8
“One of the reasons contributing to this substantial clinical and societal challenge is the high rate of treatment resistance (TR) in anxiety disorders, particularly in PD/AG, GAD, and SAD, with only about 50%–67% of patients showing sufficient clinical response to the first-line treatment [9–14].”
Ehret, F., Rogers, C. L., Fontanesi, J., Wilson, G. D., Chitti, B., Starner, J., Sidiqi, B. U., Goenka, A., Schulder, M., Bruynzeel, A. M. E., et al. (2025) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2025.08.005 · Cited by 6
Zebrafish as a Promising Model in Translational Neurobiology and Biomedicine
Kolesnikova, T. O., Ilyin, N. P., Kotova, M. M., & Калуев, А. В. (2023) · Успехи физиологических наук · doi:10.31857/s0301179823030037 · Cited by 5
Raji, M. A., Shah, R., Westra, J. R., & Kuo, Y. (2024) · Pain · doi:10.1097/j.pain.0000000000003331 · Cited by 4
Patterson, B. A., & Ameringen, M. V. (2017) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.15205 · Cited by 5
Public perceptions on using Virtual Reality and Mobile Apps in Anxiety treatment
Kirkham, R., & Baten, C. (2020) · Reinvention an International Journal of Undergraduate Research · doi:10.31273/reinvention.v13i2.625 · Cited by 6
“However, pharmaceutical response rates are estimated to be only 50–60 per cent, and critically, remission rates are as low as 25–35 per cent (Bystritsky, 2006; Roy-Byrne, 2015).”
BackgroundBokma, W. A., Batelaan, N. M., Penninx, B. W. J. H., & van Balkom, A. J. L. M. (2021) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2021.100139 · Cited by 8
Treatment-Resistant Panic Disorder
Chen, M., & Tsai, S. (2018) · Springer eBooks · doi:10.1007/978-981-10-4358-1_13 · Cited by 5
Medical Family Therapy in Psychiatry
Phelps, K. W., Hodgson, J. L., Heru, A. M., & Jensen, J. F. (2018) · Focused issues in family therapy · doi:10.1007/978-3-319-68834-3_9 · Cited by 4
Improving outcome of anxiety and obsessive-compulsive disorders
Remmerswaal, K. C. P. (2023) · doi:10.5463/thesis.227 · Cited by 3
Li, L., Li, Q., Wang, J., Fu, Q., & Chi, M. (2025) · BMC Psychiatry · doi:10.1186/s12888-025-07227-y · Cited by 8
Rassaby, M. M., Spaulding, I. G., Stein, M. B., & Taylor, C. T. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120733 · Cited by 4
Ultrasonic Neuromodulation for Network Treatments of Psychiatric and Neurological Disorders
Kubanek, J. (2026) · Biological Psychiatry · doi:10.1016/j.biopsych.2026.01.010 · Cited by 4
Metadata
- Authors
- Bystritsky, A.
- Affiliations
- University of California, Los Angeles (US)
- Corresponding author
- Bystritsky, A
- ORCID
- Bystritsky, A
- Venue
- Molecular Psychiatry
- Published
- 2006-07-18
- Volume
- 11
- Issue
- 9
- Pages
- 805-814
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2004241099
- Cited by
- 289
- References
- 88
- Citations by year
- 2026: 14 · 2025: 24 · 2024: 31 · 2023: 23 · 2022: 23 · 2021: 25 · 2020: 10 · 2019: 22 · 2018: 17 · 2017: 18 · 2016: 22 · 2015: 10 · 2014: 10 · 2013: 8 · 2012: 4
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Keywords
- anxiety disorders, treatment resistance, serotonin reuptake inhibitors, cognitive behavioral therapy, residual symptoms, suicide attempts, quality of life, chronic anxiety, biological factors, social factors
- MeSH terms
- Anxiety Disorders, Humans, United States, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.